Lucas G. Hill, Pharm.D., BCPS, BCACP

Lucas Hill headshot

Clinical Assistant Professor of Pharmacy Practice
Director of Pharmacy Addictions Research & Medicine Program

Lucas G. Hill graduated from the University of Missouri-Kansas City School of Pharmacy and completed a combined family medicine residency and faculty development fellowship in the University of Pittsburgh Medical Center Department of Family Medicine. He is now a clinical assistant professor at The University of Texas at Austin College of Pharmacy where he serves as director of the Pharmacy Addictions Research & Medicine (PhARM) Program. Dr. Hill’s research is focused on clinician-community collaborations to address substance use disorders through evidence-based treatment and harm reduction strategies. He coordinates the first year of the UT Foundations for Interprofessional Collaborative Practice curriculum and serves as lead instructor for a module that trains students from pharmacy, medicine, nursing, and social work to provide team-based care for patients with addiction. Dr. Hill provides an additional 16 hours of addiction-related instruction in the required pharmacy curriculum and precepts both the overdose prevention introductory pharmacy practice experience and the addiction medicine advanced pharmacy practice experience. He currently serves as chair of the American Association of Colleges of Pharmacy Substance Use Disorder Special Interest Group. He is also faculty advisor for the UT College of Psychiatric & Neurologic Pharmacists and co-chair for the UT Opioid Response Consortium. In 2020, Dr. Hill was awarded the American Pharmacists Association Generation Rx Award of Excellence in recognition of his outstanding contributions to addiction-related education.

National Awards

American Pharmacists Association: Generation Rx Award of Excellence (2020)
American Association of Colleges of Pharmacy: Lawrence C. Weaver Transformative Community Service Award [Group Award] (2020)
American College of Clinical Pharmacy Ambulatory Care PRN: Paper of the Year [Second Author] (2019)
Journal of the American Pharmacists Association: Outstanding Peer Reviewer (2019)
American Society of Health-System Pharmacists: CEO’s Award for Courageous Service (2018)

Regional Awards

Austin Under 40 Awards: Finalist in Medicine & Healthcare (2020)
Texas Pharmacy Association: Generation Rx Champion Award (2018)
Texas Society of Health-System Pharmacists: Best Poster Award (2018)

Local Awards – Teaching

UT College of Pharmacy: Outstanding Faculty Advisor (2019)
UT College of Pharmacy: 10 Most Impactful Faculty (2018)
UT College of Pharmacy: William Arlyn Kloesel Outstanding Preceptor (2017)
UT College of Pharmacy: ATW Regional Outstanding Preceptor (2017)
UT College of Pharmacy: IPPE Outstanding Preceptor (2017)

Local Awards – Research

UT College of Pharmacy Research Day: Best PharmD Program Poster Award (2019)
UT College of Pharmacy Research Day: Best PharmD Program Abstract Award (2019)
UT Health San Antonio Center for Service Learning Annual Conference: Best Poster Award (2019)
UT Health San Antonio Center for Service Learning Annual Conference: Blue Ribbon Award (2019)
UT Health San Antonio Center for Service Learning Annual Conference: Best Poster Award (2018)

Award Nominations

UT College of Pharmacy: Educator of the Year Award (2020)
American College of Clinical Pharmacy: New Clinical Practitioner Award (2020)
American College of Clinical Pharmacy: New Clinical Practitioner Award (2019)
American Pharmacists Association: Generation Rx Award of Excellence (2019)
Pharmacy Leadership & Education Institute: Albert B. Prescott Leadership Award (2019)
UT System: Regents’ Outstanding Teaching Award (2018)
UT College of Pharmacy: Educator of the Year Award (2017)
UT College of Pharmacy: P2 Teaching Excellence Award (2017)

Fellowships

UT College of Pharmacy: Alumni Centennial Endowed Fellowship Advisor Award ($1000) (2019–2020)
UT College of Pharmacy: Alumni Centennial Endowed Fellowship Preceptor Award ($1000) (2017–2018)

Honors

Twitter: Top 1000 Opioid Thought Leaders (2020)
UT School of Undergraduate Studies: Distinguished University Lecturer (2018)
Phi Lambda Sigma Pharmacy Leadership Society Inductee (2017)

Book Chapters

Hill LG, Jacobson AN. Opioid harm reduction. In: Dixon DL, Harris IM, eds. Ambulatory Care Self-Assessment Program: Neurologic Care and Pain Management. Lenexa, KS: American College of Clinical Pharmacy; 2019.

Hill LG. Harm reduction approaches to opioids. In: Schepis TS, ed. The Prescription Drug Abuse Epidemic: Incidence, Prevention, Treatment, and Policy. Santa Barbara, CA: ABC-CLIO, LLC; 2018: Chapter 13.

Indexed, Peer-Reviewed Manuscripts (*denotes trainee)

Coon SA, Hill LG, Hutchison RW, Arnold LM, Jarrett JB, Ottney AR, Oung AB, Painter NA, Smith MA, Stranges PM, Tran TH, McFee Winans AR, Bratberg JP. Mobilizing pharmacists to address the opioid crisis, a joint opinion of the Ambulatory Care and Adult Medicine Practice and Research Networks for the American College of Clinical PharmacyJ Am Coll Clin Pharm. Published online ahead of print September 29, 2020.

*Renfro ML, *Loera LJ, Tirado CF, Hill LG. Lofexidine for acute opioid withdrawal: A clinical case seriesMent Health Clin. 2020;10(5):259-63.

Zagorski CM, Myslinski JM, Hill LG. Isotonitazene as a contaminant of concern in the illegal opioid supply: A practical synthesis and cost perspective. Int J Drug Policy. 2020;86:102939.

Hill LG, Evoy KE, Reveles KR. Reply to a letter regarding, “Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction”. J Am Pharm Assoc. 2020;60(5):e22-3.

*Litten K, Hill LG, Garza A, Srinivasa M. Increasing naloxone knowledge and use through direct-to-patient educationJ Pharm Technol. Published online ahead of print September 11, 2020.

Mackert M, Pounders K, Brown L, Kirtz S, Hughes Wagner J, Ring D, Hill LG, Wilcox G, Murthy D, Tierney W, Innerarity S, McGlone M, Steiker LH, DeSalvo K, Bernhardt J, Pretorius K. Development of a health communication campaign to promote the Texas prescription monitoring programHealth Mark Q. 2020;37(3):1-10.

*Renfro ML, Moczygemba LR, Baumgartner J, Baumgart G, Hill LG. Type and extent of opioid-related education provided by U.S. college of pharmacy continuing education divisions. Am J Pharm Educ. Published online ahead of print June 2, 2020.

*Peterson J, Barner J, Lai P, Garza A, Hinds A, Nguyen M, Hill LG, Gums T. Impact of physician-pharmacist covisits at a primary care clinic in patients with uncontrolled diabetes. J Pharm Pract. 2020;33(3):321-5.

Hill LG, Steiker LH, *Mazin L, Kinzly ML. Implementation of a collaborative model for opioid overdose prevention on campus. J Am Coll Health. 2020;68(3):223-6.

Evoy KE, *Groff L, Hill LG, *Godinez W, *Gandhi R, Reveles KR. Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas. J Am Pharm Assoc. 2020;60:81-6.

Hill LG, *Laguado SA. Guidance for male mentors to support the safety and success of female mentees. Am J Pharm Educ. 2019;83(10):7533.

Hill LG, Evoy KE, Reveles KR. Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction. J Am Pharm Assoc. 2019:59(6):779-82.

Hill LG, Reveles KR, Evoy KE. State-level approaches to expanding pharmacists’ authority to dispense naloxone may affect accessibility. JAMA Intern Med. 2019;179(10):1442-3.

Evoy KE, Hill LG, Groff L, Mazin L, Carlson C, Reveles KR. Naloxone accessibility without a prescriber encounter under standing orders at community pharmacy chains in Texas. JAMA. 2018;320(18):1934-7.

Hill LG, *Sanchez JP, *Laguado SA, Lawson KA. Operation Naloxone: Overdose prevention service learning for student pharmacists. Curr Pharm Teach Learn. 2018;10(10):1348-53.

Murphy JE, Liles AM, Bingham AL, Chamberlin K, Dang D, Hill LG, Lee M, Leonard A, Lodise N, *Rogers E. Interprofessional education: Principles and application. An update from the American College of Clinical Pharmacy. J Am Coll Clin Pharm. 2018;1:e17-28.

Jordan RP, Bratberg J, Congdon HB, Cross LB, Hill LG, Marrs JC, McBane S, Lang WG, Ekoma JO. The report of the 2016-2017 advocacy standing committee. Am J Pharm Educ. 2017;81(8):S10.

Han JK, Hill LG, Koenig ME, Das N. Naloxone counseling for harm reduction and patient engagement. Fam Med. 2017;49(9):730-3.

Corbo JM, DeLellis TM, Hill LG, Rindfuss SL. ACE inhibitors or ARBs to prevent CKD in patients with microalbuminuria. Am Fam Physician. 2016;94(8).652-3.

Hill LG. Lorcaserin and phentermine/topiramate: Two leaps forward in weight loss pharmacotherapy. Ann Pharmacother. 2013;47(12):1740.

Research Funding

Texas Targeted Opioid Response – Operation Naloxone Expansion ($22,300,000)

  • Role: Principal Investigator
  • Sponsor: Texas Health & Human Services Commission
  • Funding Period: 5/1/2019–8/31/2022
  • Co-Investigators
    • Kasey Claborn at Dell Medical School
    • Michael Mackert at Moody College of Communication
    • Fiona Conway at Steve Hicks School of Social Work
    • Christopher Moriates at Dell Medical School

SHIFTovation Award – Operation Naloxone ($17,000)

  • Role: Principal Investigator
  • Sponsor: UT University Health Services and Counseling and Mental Health Center
  • Funding Period: 2/7/2020–12/31/2021

Evaluation of Opioid Overdose Prevention and Naloxone Counseling Provided by Community Pharmacists ($3,995)

  • Role: Co-Investigator (PI: Kirk Evoy at College of Pharmacy)
  • Sponsor: UT Health San Antonio Center for Community Service Learning
  • Funding Period: 2019­–2020

Texas Targeted Opioid Response – Prescription Monitoring Program ($3,219,840)

  • Role: Consultant (PI: Michael Mackert at Moody College of Communication)
  • Sponsor: Texas Health & Human Services Commission
  • Funding Period: 9/1/2017–8/31/2020

Texas Targeted Opioid Response – Operation Naloxone ($2,587,149)

  • Role: Principal Investigator
  • Sponsor: Texas Health & Human Services Commission
  • Funding Period: 7/1/2017–4/30/2019
  • Co-Principal Investigator
    • Lori Holleran Steiker at Steve Hicks School of Social Work

Operation Naloxone – Community Overdose Prevention Training ($28,000)

  • Role: Co-Investigator (PI: Kirk Evoy at College of Pharmacy)
  • Sponsor: UT Health San Antonio Center for Community Service Learning
  • Funding Period: 2018–2019

Naloxone Training for the Student Faculty Collaborative Practice at UT Health San Antonio ($1,225)

  • Role: Co-Investigator (PI: Kirk Evoy at College of Pharmacy)
  • Sponsor: UT Health San Antonio Center for Community Service Learning
  • Funding Period: 2018–2019

Operation Naloxone – Interprofessional Overdose Prevention Service Learning Expanded ($3,344)

  • Role: Co-Investigator (PI: Kirk Evoy at College of Pharmacy)
  • Sponsor: UT Health San Antonio Center for Community Service Learning
  • Funding Period: 2018–2019

Operation Naloxone – Interprofessional Overdose Prevention Service Learning ($4,000)

  • Role: Co-Investigator (PI: Kirk Evoy at College of Pharmacy)
  • Sponsor: UT Health San Antonio Center for Community Service Learning
  • Funding Period: 2017–2018
Contact Information
Phone:
Campus location:
PHR 2.222G

US Mail Address:
The University of Texas at Austin
PHR 2.222G
2409 University Avenue, A1910
Austin, TX 78712

CV

Twitter

LinkedIn

ResearchGate

ORCID

Operation Naloxone